Summary
Draft guidance recommending practices for use of AI to generate information intended to support regulatory decisions for drugs/biologics, including transparency, validation, and risk management.
Healthcare Implications
Sponsors using AI in clinical development and CMC should align methods and documentation with U.S. Food and Drug Administration expectations, improving credibility and reproducibility of AI‑derived evidence.